Outcomes in patients with B-ALL after CAR19/22 T-cell cocktail therapy. (A) CIR in B-ALL cohort. CIR was calculated, with nonrelapse mortality and subsequent allo-HSCT considered as competing risks. Patients who did not have a relapse at last follow-up were censored. The CIR at month 12 was 0.291 (95% CI, 0.200-0.423). (B) CIR according to CNS involvement at enrollment. Relapse was more frequent in patients with CNS involvement (CNS 2) compared with patients without (CNS 1; P = .033). PFS (C) and OS (D) in this cohort. The median PFS was 13.6 months (95% CI, 6.5-NR), and the median OS was 31.0 months (95% CI, 10.6-NR). PFS (E) and OS (F) according to leukemia burden in BM. In the patients with low leukemia burden (<5% BM blasts) at baseline, the median PFS and OS were NR. In the patients with high leukemia burden (≥5% BM blasts) at baseline, the median PFS was 8.6 months (95% CI, 5.2-15.4) and the median OS was 16.2 months (95% CI, 8.9-31.0). PFS (G) and OS (F), according to CNS involvement. In the patients without CNS involvement (CNS 1) at baseline, the median PFS was 14.9 months (95% CI, 7.8-NR), and the median OS was 31.0 months (95% CI, 10.6-NR). In the patients with CNS involvement (CNS 2) at baseline, the median PFS was 4.9 months (95% CI, 1.0-7.9), and the median OS was 16.7 months (95% CI, 1.0-NR).